Radio and PodcastRadio and PodcastLive Radio & Podcasts
Vepdegestrant artwork
Science & Medicine

Vepdegestrant

OncoPharm by OncoPharmPod

May 7, 202600:11:35Science & Medicine

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice. Check out th...

About This Episode

Vepdegestrant is an episode from OncoPharm by OncoPharmPod. The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implicat...

Podcast

This episode belongs to OncoPharm.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published May 7, 2026, 00:11:35 long, audio available.

Related Episodes

Continue listening to more episodes from OncoPharm.

Asco '26

Jun 11, 2026 - 00:25:38

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302...

Pivekimab sunirine

May 28, 2026 - 00:13:49

Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic...

IMHOTEP, PJP, and more

May 14, 2026 - 00:09:59

This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pC...

Targets Trop 2

Apr 30, 2026 - 00:12:41

This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in...

Promising Pancreatic Cancer Data

Apr 23, 2026 - 00:13:56

This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has...

ICI-Induced T1DM

Apr 16, 2026 - 00:13:24

Bibliography: 1.. 2019 Systematic Review of Published Cases: 2. Mass General Data & Publication: 3. Japan...